Document is current
Any future updates will be listed below
-
Authors
Lilli, Alessio
Parollo, Matteo
Mazzocchetti, Lorenzo
De Sensi, Francesco
Rossi, Andrea
Notarstefano, Pasquale
Santoro, Amato
Aquaro, Giovanni Donato
Cresti, Alberto
Lapira, Federica
Faggioni, Lorenzo
Tessa, Carlo
Pauselli, Luca
Bongiorni, Maria Grazia
Berruezo, Antonio
Zucchelli, Giulio http://orcid.org/0000-0001-7274-4541
-
Funding
Funding for this research was provided by:
Regione Toscana (DD 975 16/01/2020 Bando Ricerca Salute 2018)
- License Information
-
More Information
Article History
Received: 30 December 2021
Accepted: 23 March 2022
First Online: 14 April 2022
Declarations
:
: The VOYAGE trial was reviewed and approved by the Comitato Etico Area Vasta Nord Ovest (CEAVNO) (approval number 17288, 14/05/2020). The study will be carried out in accordance with recognized ethical principles and good clinical practice for clinical trials. Written informed consent will be obtained from all patients (see Supplementary files for consent forms) by specialists of clinical centers involved in the trial. It will ensure the protection of individuals as recommended in the Oviedo Convention and the Declaration of Helsinki. VOYAGE trial is registered on ClinicalTrials.gov. Trial registration: NCT04694079, registered on January 1, 2021. ExternalRef removed
: Not applicable.
: AB holds stock in Galgo Medical SL; and has received financial support from Siemens Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
